

Prediction tool helps tailor lung cancer screening to patients

30 May 2018



(HealthDay)—Personalizing the harm-benefit assessment of low-dose computed tomography (LDCT) screening for lung cancer can inform patient-centered screening decisions, according to a study published online May 29 in the *Annals of Internal Medicine*.

Tanner J. Caverly, M.D., from the University of Michigan in Ann Arbor, and colleagues examined factors that influence when LDCT [screening](#) is patient preference-sensitive using data from two large randomized trials and the Surveillance, Epidemiology, and End Results cancer registry.

In base-case analysis, the researchers found that moderate differences in preferences about the downsides of LDCT screening influenced whether screening was appropriate for eligible persons with annual lung [cancer](#) risk

APA citation: Prediction tool helps tailor lung cancer screening to patients (2018, May 30) retrieved 22 June 2022 from <https://medicalxpress.com/news/2018-05-tool-tailor-lung-cancer-screening.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.